Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
New Technology for Vaccines and Vaccine-Preventable Diseases
share announcement

New Technology for Vaccines and Vaccine-Preventable Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 1237

Special Issue Editor

Dr. Jue Liu

E-Mail Website
Guest Editor
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
Interests: epidemiology of infectious diseases; prevention; control and management of infectious diseases; maternal and child health; big data research and application in health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue on New Technologies for Vaccines and Vaccine-Preventable Diseases. The development of vaccines has long been a cornerstone of global public health, saving millions of lives by preventing infectious diseases. With the advent of new technologies, the landscape of vaccine development has dramatically transformed. Cutting-edge platforms like mRNA vaccines, viral vector-based vaccines, and AI-driven tools are revolutionizing the speed, efficacy, and accessibility of vaccines. As infectious diseases continue to evolve and new pathogens emerge, the need for innovative vaccine solutions has never been more pressing. Advances in vaccine technologies not only promise to address longstanding health challenges but also provide new strategies for preventing future pandemics. The integration of artificial intelligence, big data, and other digital technologies into vaccine research opens up unprecedented opportunities for understanding epidemiology, predicting disease outbreaks, and accelerating vaccine design. This Special Issue will showcase the latest developments in the field, highlighting the critical role these innovations play in tackling both current and future global health threats.

In this Special Issue, original research articles, reviews, meta-analyses, commentaries, and short communications are welcome. Research areas may include (but are not limited to) the following:

  • Innovative vaccine technologies: new vaccine platforms and vaccine delivery systems; vaccine efficacy and safety of new vaccines; and vaccines for newly recognized or re-emerging infectious diseases.
  • Vaccine distribution and accessibility: improving global vaccine access.
  • Immunology of vaccine responses: cellular and humoral immunity in new vaccines.
  • Artificial intelligence and big data: applications in vaccine-preventable disease epidemiology, disease prediction, vaccine development, and understanding vaccine-induced immunity.

We look forward to receiving your contributions that push the boundaries of vaccine science and technology.

Dr. Jue Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • artificial intelligence in vaccines
  • big data in vaccine research
  • emerging infectious diseases
  • vaccine accessibility
  • vaccine delivery systems
  • vaccine efficacy and safety
  • vaccine-preventable diseases
  • vaccine technology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1172 KiB  
Article
The Immunogenicity of Glutaraldehyde Inactivated PTx Is Determined by the Quantity of Neutralizing Epitopes
by Xi Wang, Xinyue Cui, Chongyang Wu, Ke Tao, Shuyuan Pan and Wenming Wei
Vaccines 2025, 13(8), 817; https://doi.org/10.3390/vaccines13080817 - 31 Jul 2025
Viewed by 273
Abstract
Background/Objectives: Chemically or genetically detoxified pertussis toxin (PTx) is a crucial antigen component of the acellular pertussis vaccine. Chemical detoxification using glutaraldehyde generally causes significant structural changes to the toxin. However, how these structural changes in PTx affect its antigenic properties remains unclear. [...] Read more.
Background/Objectives: Chemically or genetically detoxified pertussis toxin (PTx) is a crucial antigen component of the acellular pertussis vaccine. Chemical detoxification using glutaraldehyde generally causes significant structural changes to the toxin. However, how these structural changes in PTx affect its antigenic properties remains unclear. Additionally, there is limited knowledge regarding how many alterations in antigenic properties impact immunogenicity. Methods: To investigate the impact of structural changes on antigenic properties, we developed a sandwich ELISA to quantify the neutralizing epitopes on PTx. Subsequently, we analyzed different PTx toxoid (PTd) preparations with the assay. Additionally, we assessed the immunogenicity of various acellular pertussis vaccine candidates containing these PTd preparations. Finally, the assay was applied to evaluate the consistency of commercial batches of PTx and PTd intermediates. Results: The assay demonstrated reasonable specificity, accuracy, and precision, and it was sensitive enough to quantify variations in neutralizing epitopes among different PTd samples that shared the same protein concentration. Importantly, we found a positive correlation between the number of neutralizing epitopes in detoxified PTx and its immunogenicity, indicating that the amount of neutralizing epitopes present determines the immunogenicity of glutaraldehyde-inactivated PTx. Moreover, commercial batches of PTx and PTd intermediates exhibited minor variations in neutralizing epitopes. Conclusions: These findings have significant implications for developing acellular pertussis vaccines as they highlight the importance of preserving the neutralizing epitopes of PTx during detoxification to ensure the vaccine’s effectiveness. This assay is also valuable for the quality control of PTd as it more accurately represents the actual antigenic changes of PTx. Full article
(This article belongs to the Special Issue New Technology for Vaccines and Vaccine-Preventable Diseases)
►▼ Show Figures

Figure 1

15 pages, 250 KiB  
Article
Coverage and Vaccine Hesitancy of Influenza Vaccination Among Reproductive-Age Women (18–49 Years Old) in China: A National Cross-Sectional Study
by Jie Deng, Chenyuan Qin, Min Liu and Jue Liu
Vaccines 2025, 13(7), 752; https://doi.org/10.3390/vaccines13070752 - 14 Jul 2025
Viewed by 511
Abstract
Background: Influenza is a significant global respiratory infection, and vaccinating reproductive-age women, particularly in densely populated countries like China, cannot be overlooked. In this study, we aimed to determine influenza vaccination coverage, vaccine hesitancy, as well as associated factors among Chinese women [...] Read more.
Background: Influenza is a significant global respiratory infection, and vaccinating reproductive-age women, particularly in densely populated countries like China, cannot be overlooked. In this study, we aimed to determine influenza vaccination coverage, vaccine hesitancy, as well as associated factors among Chinese women aged 18–49 years old. Methods: A cross-sectional survey among women aged 18–49 years was conducted in China from 15 to 30 March 2023. We collected information such as past-year influenza vaccination, demographic characteristics, health-related factors, COVID-19-related factors, and perceived susceptibility and severity of influenza. Influenza vaccine acceptance among participants who did not receive influenza vaccination in the past year was also investigated. Multivariable logistic regression analyses were employed to investigate the influencing factors of vaccine coverage and vaccine hesitancy. Results: A total of 1742 reproductive-aged women were included in the final analysis. The past-year influenza vaccine coverage among women aged 18–49 years old was only 39.32% in China. Age ≥ 35 years (aOR = 0.72, 95% CI: 0.56–0.94), renting accommodation (aOR = 0.57, 95% CI: 0.44–0.75), and history of COVID-19 infection (aOR = 0.65, 95% CI: 0.47–0.89) and COVID-19 vaccine hesitancy (aOR = 0.39, 95% CI: 0.29–0.54) were all identified as negative correlates of influenza vaccine coverage among Chinese reproductive-aged women, while participants with a history of chronic diseases (aOR = 1.57, 95% CI: 1.23–2.01) and noticeable pandemic fatigue due to COVID-19 (aOR = 1.45, 95% CI: 1.05–2.00) were prone to have higher vaccination rates. Among reproductive-aged women who did not receive influenza vaccination in the past year, the hesitancy rate regarding future influenza vaccination was 31.79%. Factors such as older age, urban residence, living with others, poor self-rated health status, absence of chronic diseases, completion of full COVID-19 vaccination, COVID-19 vaccine hesitancy, pandemic fatigue, and failure to perceive the susceptibility and severity of influenza might increase influenza vaccine hesitancy. Discussion: Overall, a lower coverage rate of influenza vaccine was notably observed among Chinese reproductive-age women, as well as the hesitancy regarding future vaccination. To effectively mitigate the impact of influenza and reduce the incidence of associated diseases, it is imperative to devise targeted intervention strategies and policies tailored to reproductive-age women. Full article
(This article belongs to the Special Issue New Technology for Vaccines and Vaccine-Preventable Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop